Telo Genomics Corp. TELO.V
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada · telodx.com
Telo Genomics Corp. is a Canadian molecular diagnostics company headquartered in Toronto, Ontario, developing the TeloView platform for telomere-based disease prediction. The platform measures the 3D structure and spatial organization of telomeres to predict disease risks and treatment outcomes in oncology and neurological diseases. The company's lead product, TeloView-SMM, targets patients with smoldering multiple myeloma at high risk of progression to active disease.
Key ratios
ReturnOnAssets TTM -1.2
ReturnOnAssets 2025 -1.8
ReturnOnAssets 2024 -0.87
ReturnOnAssets 2023 -0.61
ReturnOnEquity TTM -4.38
ReturnOnEquity 2025 -4.92
ReturnOnEquity 2024 -1.69
ReturnOnEquity 2023 -1.08
Recent news
Telo Genomics Provides Positive Interim Data from Ongoing Clinical Trial Advancing Genomic Instability-Based Relapse Risk Assessment
2026-07-16 · Newsfile
Telo Genomics Announces Termination of Investor Relations Agreement
2026-06-26 · Newsfile Corp
Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma
2026-04-14 · Newsfile Corp
Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman
2026-03-31 · Newsfile Corp